Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.85 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.85 |
| ▸ | HPGD | P15428 | 5/20 | 0.85 |
| ▸ | APOBEC3G | Q9HC16 | 3/20 | 0.85 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.85 |
| ▸ | GFER | P55789 | 2/20 | 0.85 |
| ▸ | LMNA | P02545 | 1/20 | 0.85 |
| ▸ | PRNP | P04156 | 1/20 | 0.85 |
| ▸ | PPARG | P37231 | 1/20 | 0.85 |
| ▸ | NCOA2 | Q15596 | 1/20 | 0.85 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.85 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.85 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.85 |
| ▸ | HTT | P42858 | 2/20 | 0.61 |
| ▸ | CUL4A | Q13619 | 1/20 | 0.61 |
| ▸ | PKM | P14618 | 1/20 | 0.61 |
| ▸ | TSHR | P16473 | 1/20 | 0.60 |
| ▸ | GAA | P10253 | 5/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4626807 | 0.92 | HPGD (0.85) | KDM4EALDH1A1HPGDAPOBEC3GHSD17B10 | |
| SCHEMBL8978592 | 0.92 | KDM4E (1.00) | KDM4EALDH1A1HPGDAPOBEC3GHSD17B10 | |
| SCHEMBL14345075 | 0.85 | KDM4E (0.62) | KDM4EALDH1A1HPGDAPOBEC3GHSD17B10 | |
| SCHEMBL7691829 | 0.80 | HPGD (0.91) | KDM4EALDH1A1HPGDHSD17B10GFER | |
| SCHEMBL8978622 | 0.79 | HPGD (0.79) | KDM4EALDH1A1HPGDAPOBEC3GHSD17B10 | |
| SCHEMBL28911095 | 0.77 | KDM4E (0.71) | KDM4EALDH1A1HPGDAPOBEC3GHSD17B10 | |
| SCHEMBL8930409 | 0.76 | KDM4E (0.73) | KDM4EALDH1A1HPGDAPOBEC3GHSD17B10 | |
| SCHEMBL13983416 | 0.76 | ALDH1A1 (0.71) | KDM4EALDH1A1HPGDAPOBEC3GHSD17B10 | |
| SCHEMBL13983077 | 0.75 | KDM4E (0.61) | KDM4EALDH1A1HPGDAPOBEC3GHSD17B10 | |
| SCHEMBL8978530 | 0.75 | GFER (0.74) | KDM4EALDH1A1HPGDAPOBEC3GHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2298748-B1 | Triazole compounds that modulate HSP90 activity | SYNTA PHARMACEUTICALS CORP (US) | 2016-07-20 | — | — | EP | disclosed |
| EP-2295416-B1 | Triazole compounds that modulate HSP90 activity | SYNTA PHARMACEUTICALS CORP (US) | 2016-01-27 | — | — | EP | disclosed |
| US-9108933-B2 | Method for treating proliferative disorders associated with mutations in c-Met | SYNTA PHARMACEUTICALS CORP. (US) | 2015-08-18 | — | — | US | disclosed |
| US-9108933-B2 | Method for treating proliferative disorders associated with mutations in c-Met | SYNTA PHARMACEUTICALS CORP. (US) | 2015-08-18 | — | — | US | disclosed |
| US-9101614-B2 | Method for treating non-Hodgkin's lymphoma | SYNTA PHARMACEUTICALS CORP. (US) | 2015-08-11 | — | — | US | disclosed |
| US-9101614-B2 | Method for treating non-Hodgkin's lymphoma | SYNTA PHARMACEUTICALS CORP. (US) | 2015-08-11 | — | — | US | disclosed |
| US-20150150851-A1 | FORMULATION AND DOSING OF HSP90 INHIBITORY COMPOUNDS | SYNTA PHARMACEUTICALS CORP (US) | 2015-06-04 | — | — | US | disclosed |
| US-20150150851-A1 | FORMULATION AND DOSING OF HSP90 INHIBITORY COMPOUNDS | SYNTA PHARMACEUTICALS CORP (US) | 2015-06-04 | — | — | US | disclosed |
| US-20150094349-A1 | Method for Treating Proliferative Disorders Associated with Protooncogene Products | SYNTA PHARMACEUTICALS CORP (US) | 2015-04-02 | — | — | US | disclosed |
| US-20150094349-A1 | Method for Treating Proliferative Disorders Associated with Protooncogene Products | SYNTA PHARMACEUTICALS CORP (US) | 2015-04-02 | — | — | US | disclosed |
| US-20080125587-A1 | Synthesis of triazole compounds that modulate HSP90 activity | SYNTA PHARMACEUTICALS CORP. | 2008-05-29 | — | — | US | disclosed |
| WO-2008021364-A2 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | SYNTA PHARMACEUTICALS CORP. (US) | 2008-02-21 | — | — | WO | disclosed |
| US-20080027047-A1 | Compounds that modulate HSP90 activity and methods for identifying same | SYNTA PHARMACEUTICALS CORP | 2008-01-31 | — | — | US | disclosed |
| US-20080027047-A1 | Compounds that modulate HSP90 activity and methods for identifying same | SYNTA PHARMACEUTICALS CORP | 2008-01-31 | — | — | US | disclosed |
| US-20080004276-A1 | Method for treating non-hodgkin's lymphoma | LSI FINANCING LLC, AS ADMINISTRATIVE AGENT | 2008-01-03 | — | — | US | disclosed |
| US-20080004276-A1 | Method for treating non-hodgkin's lymphoma | LSI FINANCING LLC, AS ADMINISTRATIVE AGENT | 2008-01-03 | — | — | US | disclosed |
| US-20080004266-A1 | Method for treating proliferative disorders associated with protooncogene products | LSI FINANCING LLC, AS ADMINISTRATIVE AGENT | 2008-01-03 | — | — | US | disclosed |
| US-20080004266-A1 | Method for treating proliferative disorders associated with protooncogene products | LSI FINANCING LLC, AS ADMINISTRATIVE AGENT | 2008-01-03 | — | — | US | disclosed |
| WO-2007139960-A2 | COMPOUNDS THAT MODULATE HSP90 ACTIVITY AND METHODS FOR IDENTIFYING SAME | SYNTA PHARMACEUTICALS CORP. (US) | 2007-12-06 | — | — | WO | disclosed |
| WO-2007139952-A2 | METHOD FOR THE PREPARATION OF TRIAZOLE COMPOUNDS WITH HSP90 MODULATING ACTIVITY | SYNTA PHARMACEUTICALS CORP. (US) | 2007-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080125587-A1 | Synthesis of triazole compounds that modulate HSP90 activity | HSP90AB1, HSP90AA1, HSP90AB2P | KDM4E 2835/4885ALDH1A1 246/4885HPGD 561/4885 |
| US-20150094349-A1 | Method for Treating Proliferative Disorders Associated with Protooncogene Products | HSP90AB1, HSP90AB2P, HSP90AA1 | KDM4E 2879/4885ALDH1A1 1385/4885HPGD 2124/4885 |
| US-20080004276-A1 | Method for treating non-hodgkin's lymphoma | HSP90AB1, HSP90AB2P, HSP90B1 | KDM4E 2790/4885ALDH1A1 1036/4885HPGD 210/4885 |
| US-20150150851-A1 | FORMULATION AND DOSING OF HSP90 INHIBITORY COMPOUNDS | HSP90AB1, HSP90AA1, HSP90AB2P | KDM4E 4422/4885ALDH1A1 2514/4885HPGD 498/4885 |
| US-20080027047-A1 | Compounds that modulate HSP90 activity and methods for identifying same | HSP90AB1, HSP90B1, CDC37 | KDM4E 3500/4885ALDH1A1 2231/4885HPGD 534/4885 |
| US-20080004266-A1 | Method for treating proliferative disorders associated with protooncogene products | HSP90AB1, HSP90AB2P, HSP90AA1 | KDM4E 2879/4885ALDH1A1 1385/4885HPGD 2124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.